{"id":565679,"date":"2024-03-29T09:04:00","date_gmt":"2024-03-29T13:04:00","guid":{"rendered":"https:\/\/platohealth.ai\/mri-screening-detects-prostate-cancer-among-men-with-germline-mutations-renal-and-urology-news-renal-platohealth-ai\/"},"modified":"2024-03-30T01:28:15","modified_gmt":"2024-03-30T05:28:15","slug":"mri-screening-detects-prostate-cancer-among-men-with-germline-mutations-renal-and-urology-news-renal-platohealth-ai","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/mri-screening-detects-prostate-cancer-among-men-with-germline-mutations-renal-and-urology-news-renal-platohealth-ai\/","title":{"rendered":"MRI Screening Detects Prostate Cancer Among Men With Germline Mutations – Renal And Urology News – Renal.PlatoHealth.ai","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n

For men with germline mutations, MRI-based screening increases prostate cancer detection while cutting down on the number of unnecessary prostate biopsies, investigators report.<\/p>\n

In the PROGRESS prostate cancer screening trial, 101 male germline carriers of a likely pathogenic variant in at least 1 of the 19 prostate cancer risk genes have completed the first round of screening so far. BRCA2, BRCA1,<\/em> and ATM<\/em> were the most commonly found variants. The men, aged 35-74 years, received annual PSA screening and digital rectal examination (DRE) with multiparametric MRI (mpMRI) of the prostate every 3 years.<\/p>\n

Of the 101 men, 21 had an elevated age-adjusted PSA, abnormal DRE, or suspicious mpMRI and underwent a biopsy<\/a>. Age-adjusted PSA thresholds were more than 1.5 ng\/mL for men 35-49 years, 2.0 ng\/mL for 50-54 years, and 3.0 ng\/mL for 55-74 years. Of the 9 cancer cases, 7 were clinically significant with a PIRADS score of 3 or higher.<\/p>\n

In this high-risk cohort, mpMRI showed 100% sensitivity and a 100% negative predictive value for prostate cancer detection on biopsy, whereas PSA-based screening<\/a> alone had 57% sensitivity with a negative predictive value of 73%, Keyan Salari, MD, PhD, of Massachusetts General Hospital in Boston, and colleagues reported in European Urology Oncology.<\/em><\/p>\n

According to the investigators, \u201cMRI-based screening<\/a> alone achieved superior net benefit at all threshold probabilities compared with PSA screening\u2014detecting one additional cancer case per 7.5 patients, while avoiding more unnecessary biopsies at the same threshold probability.\u201d<\/p>\n

\n

Related Content<\/p>\n<\/div>\n

They noted that no cancers were diagnosed among the 5 patients aged 35-39 years reinforcing screening initiation at the age of 40 years.<\/p>\n